Maa: Irlanti
Kieli: englanti
Lähde: HPRA (Health Products Regulatory Authority)
Baclofen
Novartis Ireland Limited
M03BX; M03BX01
Baclofen
10 milligram(s)
Tablet
Product subject to prescription which may be renewed (B)
Other centrally acting agents; baclofen
Marketed
1983-01-18
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT LIORESAL® 10 MG TABLETS (BACLOFEN) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only . Do not pass it onto others. It may harm them even if their signs of illness are the same as yours If you get any side effects , talk to your doctoor or pharmacist This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Lioresal is and what it is used for 2. What you need to know before you take Lioresal 3. How to take Lioresal 4. Possible side effects 5. How to store Lioresal 6. Contents of the pack and other information 1. WHAT LIORESAL IS AND WHAT IT IS USED FOR Lioresal contains the active ingredient, baclofen. Baclofen is a muscle-relaxant drug. Lioresal is used to relieve muscle rigidity (spasticity) or spasms in adults and children, which may occur as a result of illnesses such as cerebral palsy, multiple sclerosis, cerebrovascular accidents, spinal cord diseases and other nervous system disorders. 2. What you need to know before you take Lioresal Do not take Lioresal if: you are allergic (hypersensitive) to baclofen or any of the other ingredients of Lioresal (listed in Section 6) DO NOT TAKE LIORESAL IF ANY OF THE ABOVE APPLY TO YOU. IF YOU ARE NOT SURE, TALK TO YOUR DOCTOR OR PHARMACIST BEFORE TAKING LIORESAL.TAKE SPECIAL CARE Check with your doctor or pharmacist before taking your medicine if: • you have epilepsy • you have a mental illness such as schizophrenia, psychosis, depressive or manic disorders or confusional states • you have high blood pressure • you have Parkinson’s disease • you have any liver, kidney or lung disease • you have diabetes • you have difficulties in urinating • you have a disturbance of the blood circulation in your brain Lue koko asiakirja
Health Products Regulatory Authority 28 January 2022 CRN00CS45 Page 1 of 10 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lioresal 10 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10 mg baclofen. Excipient with known effect: wheat starch 61mg/tablet For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Tablet. Circular, flat, bevelled edged white to faintly yellowish tablet with the letters ‘CG’ on one surface and ‘KJ’ on the other side with a single scoreline to facilitate breaking of the tablet for ease of swallowing. The tablet can be divided into equal doses. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Lioresal is indicated for the relief of spasticity of voluntary muscle resulting from such disorders as: multiple sclerosis, other spinal lesions, e.g. syringomyelia, motor neurone disease, transverse myelitis. Lioresal is also indicated in adults for the relief of spasticity of voluntary muscle arising from e.g. cerebrovascular accidents, cerebral palsy, meningitis, traumatic head injury. Patient selection is important when initiating Lioresal therapy; it is likely to be of most benefit in patients whose spasticity constitutes a handicap to activities and/or physiotherapy. Treatment should not be commenced until the spastic state has become stabilised. Paediatric population Baclofen is indicated in patients below 18 years for the symptomatic treatment of spasticity of cerebral origin, especially where due to infantile cerebral palsy, as well as following cerebrovascular accidents or in the presence of neoplastic or degenerative brain disease. Baclofen is also indicated for the symptomatic treatment of muscle spasms occurring in spinal cord diseases of infectious, degenerative, traumatic, neoplastic, or unknown origin such as multiple sclerosis, spastic spinal paralysis, amyotrophic lateral sclerosis, syringomyelia, transverse myelitis, traumatic paraplegia or paraparesis, and compression of the spinal cord. 4.2 POSOLOGY AND METHOD Lue koko asiakirja